ARS Pharmaceuticals, Inc. SPRY 深 滬
已收盤 04-02 16:00:00 美东时间
8.30
+0.190
+2.34%
華盛通- 最 高8.31
- 今 開7.91
- 成交量 127.73万股
- 最 低 7.72
- 昨 收 8.11
- 總市值 8.24亿
- 52周最高 18.90
- 市盈率 靜 --
- 換手率 1.29%
- 52周最低 6.66
- 委 比 -32.72%
- 總股本 9929.73万
- 歷史最高 63.41
- 量 比 0.75
- 振 幅 7.27%
- 歷史最低 2.55
- 每 手 1
- 風險率 3.10%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FDA Approves ARS Pharmaceuticals Updating Neffy 1 mg Prescribing Information To Remove Age Criteria
Children were previously required to weigh ≥33 lbs. and <66 lbs. and be at least four years of age to receive neffy 1 mg dose - approval enables families of younger children within the weight range to access a
03-27 20:02
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
<p align="center"><em>Children who weigh ≥33 lbs. and <66 lbs. can now access neffy 1 mg without age restrictions. Storage in blister packaging or a neffy carrying case is recommended, with carrying cases available starting this summer. neffy is indicated for emergency treatment of Type 1 allergic reactions, including anaphylaxis, in adults and children weighing 33 lbs. or greater. Key safety information includes proper administration, potenti...
03-27 12:00
Olaplex, Kodiak Sciences, Precigen And Other Big Stocks Moving Higher On Thursday
Olaplex Holdings shares surge 51% after being acquired by Henkel AG & Co. KGaA. Other big gainers include Kodiak Sciences Inc and Precigen Inc.
03-26 22:04
ARS Pharmaceuticals: Q4 Earnings Insights
ARS Pharmaceuticals (NASDAQ:SPRY) reported its Q4 earnings results on Monday, M...
03-09 19:36
ARS Pharmaceuticals Q4 EPS $(0.42) Beats $(0.44) Estimate, Sales $28.087M Beat $25.584M Estimate
ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.44) by 4.11 percent. This is a 187.5 percent decrease over earnings of $0.48 per share
03-09 19:35
Earnings Scheduled For March 9, 2026
Companies Reporting Before The Bell • ZIM Integrated Shipping (NYSE:ZIM) is exp...
03-09 19:11
财报速睇 | ARS Pharmaceuticals, Inc. 2025财年年度营收0.84亿美元，同比下降5.6%；归母净利润亏损1.71亿美元，由盈转亏
华盛资讯3月9日讯，ARS Pharmaceuticals, Inc.公布2025财年年度业绩，公司年度营收0.84亿美元，同比下降5.6%，归母净利润亏损1.71亿美元，由盈转亏。
03-09 18:35
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization
ARS Pharmaceuticals reported $72.2 million in U.S. net product revenue for neffy in 2025, the first full year of its commercial launch. Total revenue reached $84.3 million, while R&D expenses were $13.2 million and SG&A expenses were $230.1 million. Net loss for the year was $171.3 million. The company ended 2025 with a strong cash position of $245.0 million, supporting its operating plan. Key highlights include advancements in global regulatory ...
03-09 10:00
Exploring ARS Pharmaceuticals's Earnings Expectations
ARS Pharmaceuticals (NASDAQ:SPRY) is gearing up to announce its quarterly earni...
03-06 22:02
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences
ARS Pharmaceuticals, Inc. announced a conference call on March 9, 2026, to discuss 2025 financial results and business highlights. The company will also participate in investor conferences in February and March 2026, with webcasts available on its website. ARS Pharma focuses on developing epinephrine nasal spray for treating allergic reactions, including anaphylaxis, and offers its product in the U.S., EU, and China.
02-23 13:00
